The table below shows Tarsus Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$162.05M
$118.70M
$102.66M
$78.33M
$48.12M
$40.81M
Cost of revenue
$9.40M
-
-
$5.21M
-
-
Gross profit
-
-
-
-
-
-
R&D
$22.35M
$16.28M
$15.59M
$14.41M
$12.13M
$12.32M
TARS annual revenue (10-K history)
Tarsus Pharmaceuticals, Inc. reported annual revenue of $451.36M for fiscal year 2025. That is up 146.7% from $182.95M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.